Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levocetirizine: an update.

Garry M Walsh1

  • 1Department of Medicine and Therapeutics, School of Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. g.m.walsh@abdn.ac.uk

Current Medicinal Chemistry
|October 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma.

Antibodies (Basel, Switzerland)·2025
Same author

Therapeutics and Clinical Risk Management - 20<sup>th</sup> Anniversary.

Therapeutics and clinical risk management·2025
Same author

Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment.

Advances in pharmacology (San Diego, Calif.)·2023
Same author

Molecular Biology of Eosinophils: Introduction.

Methods in molecular biology (Clifton, N.J.)·2021
Same author

Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.

Expert opinion on biological therapy·2020
Same author

Dupilumab utility in difficult-to-treat asthma.

Immunotherapy·2019
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
Same journal

EGFR Dysregulation in Cancer: From Molecular Mechanisms and Key Mutations to Evolving TKI Strategies and Resistance Mitigation.

Current medicinal chemistry·2026
Same journal

DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future Therapeutic Development.

Current medicinal chemistry·2026
Same journal

Screening of Medicinal and Edible Homology Substances for Diabetic Kidney Disease Based on GraphBAN.

Current medicinal chemistry·2026
See all related articles

Levocetirizine, a new antihistamine, effectively treats allergic rhinitis and chronic urticaria. It offers rapid action, minimal metabolism, and anti-inflammatory properties, enhancing its therapeutic benefits for allergy sufferers.

Area of Science:

  • Pharmacology
  • Allergy Research
  • Drug Development

Background:

  • Histamine is central to allergic disease pathophysiology.
  • Current therapies target histamine effects.
  • Levocetirizine is a novel antihistamine agent.

Purpose of the Study:

  • To evaluate the pharmacokinetic and pharmacodynamic profile of levocetirizine.
  • To assess the safety and efficacy of levocetirizine in treating allergic conditions.
  • To explore the anti-inflammatory effects of levocetirizine.

Main Methods:

  • Pharmacokinetic studies assessing bioavailability, distribution, and metabolism.
  • Clinical trials for safety and efficacy in allergic rhinitis and chronic urticaria.
  • In vitro and in vivo studies to investigate anti-inflammatory mechanisms.

Related Experiment Videos

Main Results:

  • Levocetirizine exhibits high bioavailability and rapid onset of action.
  • It undergoes minimal hepatic metabolism and has limited distribution.
  • Clinical trials demonstrate safety and efficacy for allergic rhinitis and chronic urticaria.
  • Levocetirizine shows potent antihistamine activity and additional anti-inflammatory effects.

Conclusions:

  • Levocetirizine is a safe and effective antihistamine with favorable pharmacokinetic properties.
  • Its anti-inflammatory actions may provide enhanced therapeutic benefits in allergic diseases.
  • Levocetirizine represents a valuable therapeutic option for managing allergic conditions.